Céline Vallot's guest appearances

Céline Vallot

Epigenetics Podcast

Canal Académies - Nouveautés

Joe Fernandez

David Jones

Sir Roger Scruton

René Char

Monica Dus

Clément Marot

Catherine Pozzi

Stanislas Dehaene

Karmella Haynes

Erez Lieberman Aiden

Noe Gonzalez

Shelley Berger

Emily Bernstein

Wendy Bickmore

Gary Karpen

OwlTail

C’est un champ prometteur qui s’ouvre pour la recherche médicale. Grâce à de nouvelles approches combinatoires qui permettent d’isoler les cellules, la biologiste Céline Vallot et son équipe de l’Institut Curie étudient avec une finesse extrême les mécanismes de résistance aux traitements contre le cancer du sein. En dressant la carte d’identité des cellules tumorales, ils scrutent leurs modifications épigénétiques et cherchent à tirer profit de leur réversibilité pour les réorienter. Cette intervention sur les cellules permettrait de les rendre plus sensibles aux thérapies. À terme, Céline Vallot espère contribuer à la mise en place de traitements encore plus adaptés aux tumeurs des malades.

Céline Vallot : Comprendre les tumeurs à l&#039;échelle de la cellule

In this episode of the Epigenetics Podcast, we caught up with Céline Vallot from L'Institut Curie in Paris to discuss her work on investigating the dynamics of epigenetic plasticity in cancer with single cell technologies. During her Post-Doc years Céline Vallot worked on the inactive X chromosome. Using RNA-Seq she discovered a novel long noncoding RNA (lncRNA) called XACT. This lncRNA is expressed from and coats the active X chromosome in human pluripotent cells. Céline Vallot also showed that XACT is specific to humans and cannot be found in mice.  After starting her own lab, Céline Vallot began to focus on Single Cell Epigenomics in Cancer. She and her team developed a high-throughput single-cell ChIP-seq approach which relies on a droplet microfluidics platform to profile the chromatin landscape of thousands of cells. By doing so they could show that a subset of cells within untreated drug-sensitive tumors share a common chromatin signature. This would have been impossible with common bulk approaches. These cells are characterized by the loss of H3K27me3, which leads to stable transcriptional repression, influencing genes that are known to promote resistance to treatment. In this episode we discuss how Céline Vallot had her once-in-a-lifetime scientific eureka-moment, when, during her postdoc, she first saw XACT coating the whole X-Chromosome in humans and then how she pivoted when starting her own lab and focuses now on single-cell epigenomics in cancer.    References  Céline Vallot, Christophe Huret, … Claire Rougeulle (2013) XACT , a long noncoding transcript coating the active X chromosome in human pluripotent cells (Nature Genetics) DOI: 10.1038/ng.2530   Kevin Grosselin, Adeline Durand, … Annabelle Gérard (2019) High-throughput single-cell ChIP-seq     identifies heterogeneity of chromatin states in breast cancer (Nature Genetics) DOI: 10.1038/s41588-019-0424-9   Pacôme Prompsy, Pia Kirchmeier, … Céline Vallot (2020) Interactive analysis of single-cell epigenomic landscapes with ChromSCape (Nature Communications) DOI: 10.1038/s41467-020-19542-x   Justine Marsolier, Pacôme Prompsy, … Céline Vallot (2021) H3K27me3 is a determinant of chemotolerance in triple-negative breast cancer (bioRxiv) DOI: 10.1101/2021.01.04.423386     Related Episodes  Dosage Compensation in Drosophila (Asifa Akhtar)   Epigenetics and X-Inactivation (Edith Heard)   Cancer and Epigenetics (David Jones)     Contact  Active Motif on Twitter   Epigenetics Podcast on Twitter   Active Motif on LinkedIn   Active Motif on Facebook   Email: podcast@activemotif.com 

In this episode of the Epigenetics Podcast, we caught up with Céline Vallot from L'Institut Curie in Paris to discuss her work on investigating the dynamics of epigenetic plasticity in cancer with single cell technologies. During her Post-Doc years Céline Vallot worked on the inactive X chromosome. Using RNA-Seq she discovered a novel long noncoding RNA (lncRNA) called XACT. This lncRNA is expressed from and coats the active X chromosome in human pluripotent cells. Céline Vallot also showed that XACT is specific to humans and cannot be found in mice. After starting her own lab, Céline Vallot began to focus on Single Cell Epigenomics in Cancer. She and her team developed a high-throughput single-cell ChIP-seq approach which relies on a droplet microfluidics platform to profile the chromatin landscape of thousands of cells. By doing so they could show that a subset of cells within untreated drug-sensitive tumors share a common chromatin signature. This would have been impossible with common bulk approaches. These cells are characterized by the loss of H3K27me3, which leads to stable transcriptional repression, influencing genes that are known to promote resistance to treatment. In this episode we discuss how Céline Vallot had her once-in-a-lifetime scientific eureka-moment, when, during her postdoc, she first saw XACT coating the whole X-Chromosome in humans and then how she pivoted when starting her own lab and focuses now on single-cell epigenomics in cancer. References <ul><li> Céline Vallot, Christophe Huret, … Claire Rougeulle (2013) <a href="https://www.nature.com/articles/ng.2530" rel="nofollow" target="_blank">XACT , a long noncoding transcript coating the active X chromosome in human pluripotent cells</a> (Nature Genetics) DOI: <a href="http://dx.doi.org/10.1038/ng.2530" rel="nofollow" target="_blank">10.1038/ng.2530</a> </li> <li> Kevin Grosselin, Adeline Durand, … Annabelle Gérard (2019) <a href="https://www.nature.com/articles/s41588-019-0424-9" rel="nofollow" target="_blank">High-throughput single-cell ChIP-seq     identifies heterogeneity of chromatin states in breast cancer</a> (Nature Genetics) DOI: <a href="http://dx.doi.org/10.1038/s41588-019-0424-9" rel="nofollow" target="_blank">10.1038/s41588-019-0424-9</a> </li> <li> Pacôme Prompsy, Pia Kirchmeier, … Céline Vallot (2020) Interactive analysis of single-cell epigenomic landscapes with ChromSCape (Nature Communications) DOI: <a href="http://dx.doi.org/10.1038/s41467-020-19542-x" rel="nofollow" target="_blank">10.1038/s41467-020-19542-x</a> </li> <li> Justine Marsolier, Pacôme Prompsy, … Céline Vallot (2021) <a href="https://www.biorxiv.org/content/10.1101/2021.01.04.423386v1" rel="nofollow" target="_blank">H3K27me3 is a determinant of chemotolerance in triple-negative breast cancer</a> (bioRxiv) DOI: <a href="http://dx.doi.org/10.1101/2021.01.04.423386" rel="nofollow" target="_blank">10.1101/2021.01.04.423386</a> </li> </ul> Related Episodes <ul><li> <a href="https://www.activemotif.com/podcasts#asifa-akhtar" rel="nofollow" target="_blank">Dosage Compensation in Drosophila (Asifa Akhtar)</a> </li> <li> <a href="https://www.activemotif.com/podcasts#edith-heard" rel="nofollow" target="_blank">Epigenetics and X-Inactivation (Edith Heard)</a> </li> <li> <a href="https://www.activemotif.com/podcasts#david-jones" rel="nofollow" target="_blank">Cancer and Epigenetics (David Jones)</a> </li> </ul> Contact <ul><li> <a href="https://twitter.com/activemotif" rel="nofollow" target="_blank">Active Motif on Twitter</a> </li> <li> <a href="https://twitter.com/epigenetics_pod" rel="nofollow" target="_blank">Epigenetics Podcast on Twitter</a> </li> <li> <a href="https://www.linkedin.com/company-beta/35651/" rel="nofollow" target="_blank">Active Motif on LinkedIn</a> </li> <li> <a href="https://www.facebook.com/ActiveMotifInc/" rel="nofollow" target="_blank">Active Motif on Facebook</a> </li> <li> Email: <a href="mailto:podcast@activemotif.com">podcast@activemotif.com</a> </li></ul>

Investigating the Dynamics of Epigenetic Plasticity in Cancer with Single Cell Technologies (Céline Vallot)